background late asthmatic reaction lar associated mucosal inflammation involving cell types including activated t lymphocytes eosinophils contrast early asthmatic reaction ear considered results rapid release bronchoconstrictor mediators ige sensitised mast cells cyclosporin efficacy chronic severe asthma believed act principally inhibiting cytokine mrna transcription t lymphocytes effects cell types vitro including inhibition events mast cells hypothesised cyclosporin attenuate ear lar subjects mild asthma methods sensitised atopic asthmatic subjects documented dual asthmatic responses studied double blind placebo controlled crossover trial separate study visits subjects received oral doses cyclosporin matched placebo inhaled allergen challenges forced expiratory volume second fev1 measured half hourly hours blood eosinophil counts analysed NUMBER hours challenge treatment effects blood eosinophil counts ear lar respectively defined areas curve auc fev1 changes baseline hours challenge compared crossover analysis results cyclosporin reduced lar median auc 1h interquartile range cyclosporin 1h placebo p NUMBER late increase blood eosinophils median NUMBER x NUMBER NUMBER cyclosporin NUMBER x NUMBER NUMBER placebo p NUMBER effect ear reduction lar cyclosporin correlated significantly prechallenge blood concentrations cyclosporin r NUMBER p NUMBER conclusions data consistent concept cyclosporin actions asthma resulting inhibition mrna transcription cytokines predominantly t lymphocytes cyclosporin possibly inhaled form agents prevent cytokine gene transcription potential ameliorating inflammatory component asthma allergen induced allergen induced corticosteroid dependent NUMBER NUMBER NUMBER NUMBER non parametric NUMBER NUMBER NUMBER NUMBER NUMBER NUMBER anti inflammatory eosinophil active exocytosis degranulation NUMBER NUMBER NUMBER NUMBER